A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 hour, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

This article is protected by copyright. All rights reserved.

Source: American Journal of Hematology - February 17, 2017 Category: Hematology Authors: James Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger Lyons, Wael Harb, Hesham Mohamed, Ali Nourbakhsh, Robert Rifkin Tags: Research Article Source Type: research